What is Marjolin's ulcer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Marjolin's Ulcer?

Marjolin's ulcer is a rare, aggressive cutaneous malignancy—most commonly squamous cell carcinoma—that develops in chronically traumatized, inflamed skin, particularly in burn scars, chronic wounds, pressure ulcers, and areas of long-standing inflammation. 1, 2

Clinical Definition and Pathogenesis

Marjolin's ulcer represents malignant transformation occurring in previously injured tissue, with the term originally described by Jean-Nicolas Marjolin in 1828. 1, 2 While classically associated with burn scars, this malignancy can arise from multiple chronic wound types including:

  • Burn scars (most common etiology) 1, 3
  • Traumatic wounds and lacerations 2, 3
  • Chronic pressure ulcers 4, 5, 6
  • Venous stasis ulcers 2, 5
  • Osteomyelitis sinus tracts 1
  • Vaccination sites, snake bites, pilonidal abscesses 1
  • Fistulas and leprosy ulcers 2

The proposed pathogenic mechanisms include toxins from damaged tissues, immunologic dysfunction, cocarcinogens, chronic irritation, poor lymphatic regeneration, and local mutations. 1

Epidemiology and Latency Period

The incidence of malignant transformation in burn scars ranges from 0.77% to 2%, though one study found 0.7% incidence among patients with existing scars. 1, 3

Two distinct variants exist:

  • Chronic form (more common): Develops slowly with an average latency period of 25-35 years from initial injury to malignant transformation 1, 2, 3
  • Acute form (rare): Carcinoma occurs within 1 year of injury 1

A critical finding is that younger patients at the time of initial injury tend to have longer latency periods (negative correlation: r = -0.8, P <0.01), with the pre-ulceration and post-ulceration periods also inversely related to age at injury (r = -0.7, P <0.01). 3

Clinical Presentation

Anatomic distribution: All body parts can be affected, but extremities and scalp are most frequently involved, with pelvic and flank regions also commonly affected. 1, 6

Clinical warning signs include:

  • Atrophic and unstable scars showing tendency toward malignant degeneration 1
  • Skin breakdown on chronic scars 3
  • Chronic unhealed ulcers that fail to respond to standard wound care 2, 5
  • Repeated ulceration in previously healed scar tissue 3

The mean post-ulceration period (from ulcer development to diagnosis) averages 7 years, emphasizing the insidious nature of this malignancy. 3

Histopathology

Well-differentiated squamous cell carcinoma is the predominant histological type, though various other cell types can occur. 1, 2, 5 Biopsy with histopathologic interpretation remains the gold standard for diagnosis. 2

Aggressive Behavior and Prognosis

Marjolin's ulcers behave significantly more aggressively than typical cutaneous squamous cell carcinomas, with:

  • Higher rates of regional lymph node metastases 1, 6
  • Greater propensity for local recurrence 6
  • Poor prognosis when nodal metastases are present—all four patients with positive lymph nodes in one series died of systemic disease 6
  • Deaths from Marjolin's ulcer are not uncommon 1

High-grade tumors carry particularly grave prognosis due to nodal involvement. 6

Management Principles

Radical surgical excision is the treatment of choice, though consensus on prophylactic lymph node dissection remains lacking. 1, 2, 5 Major oncologic surgical procedures are required to eradicate the cancer. 6

Early recognition and proper staging offer the best chance for cure. 6 Supplementary therapy may be needed given the high metastatic risk and potential for vital organ involvement. 5

Prevention and Surveillance

A critical pitfall is that Marjolin's ulcer is frequently overlooked and inadequately treated, leading to poor outcomes. 2, 5

Prevention strategies include:

  • Meticulous wound care for all burn injuries and chronic wounds 1
  • Close surveillance during the latency period, particularly monitoring for skin breakdown on chronic scars 3
  • High index of suspicion when evaluating any chronic, non-healing wound—this applies to all healthcare providers managing patients with long-standing wounds 2, 5
  • Increased oncological alertness by nursing and medical personnel caring for patients with chronic wounds, pressure sores, and leg ulcers 5

The latency period represents a critical window for prevention through vigilant monitoring and early intervention when ulceration occurs. 3

References

Research

Marjolin's ulcer: a preventable complication of burns?

Plastic and reconstructive surgery, 2009

Research

Marjolin ulcer: an overlooked entity.

International wound journal, 2011

Research

Marjolin's ulcer: a preventable malignancy arising from scars.

World journal of surgical oncology, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Marjolin's ulcer in chronic wounds - review of available literature.

Contemporary oncology (Poznan, Poland), 2017

Research

Marjolin ulcers: secondary carcinomas in chronic wounds.

Journal of the Southern Orthopaedic Association, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.